Navigation Links
Atherothrombosis Patients at High Risk for CV Events

A large, international study finds that patients with arterial disease have relatively high risk of experiencing a cardiovascular// event (such as heart attack, stroke or cardiovascular death) within one year. This study is published in the March 21 issue of JAMA.

Atherothrombosis (arterial disease, such as coronary artery disease [CAD], cerebrovascular disease [CVD], and peripheral arterial disease [PAD]; narrowing of the arteries that supply the legs and feet]) is associated with the main causes of death on a worldwide scale, according to background information in the article.

"Recent U.S. data have confirmed that, despite a decrease in age-standardized national death rates, the absolute number of deaths from these conditions continues to increase, and prevalence is sharply increasing in other parts of the world. Thus, atherothrombotic diseases are, and are projected still to be, the leading cause of death worldwide by 2020." Few studies have documented the current cardiovascular (CV) event rates in outpatients with atherothrombosis.

Ph. Gabriel Steg, M.D., of the H?pital Bichat-Claude Bernard, Paris, and colleagues examined the characteristics and CV event rates of patients for whom 1-year follow-up data were available from the Reduction of Atherothrombosis for Continued Health (REACH) Registry, an international group of 68,236 patients with either established atherosclerotic arterial disease (such as CAD, PAD, CVD; n = 55,814) or at least three risk factors for atherothrombosis (n = 12,422). The participants were enrolled from 5,587 physician practices in 44 countries in 2003-2004.

As of July 2006, 1-year outcomes were available for 95 percent (n = 64,977) of participants. The researchers found that in the overall stable population with established arterial disease, approximately 1 in 7 patients had a cardiovascular event (CV death, heart attack, and stroke) or was hospitalized for a CV event or revascularization procedure within a year of enrollment. Patients with established arterial disease experienced 2 to 3 times higher event rates than patients with multiple risk factors only.

The overall combined CV death, heart attack, or stroke rate at 1 year was 4.24 percent, ranging from 2.15 percent of patients with multiple risk factors only to 6.47 percent of patients enrolled with CVD and 4.69 percent for those with established atherosclerotic arterial disease.

Among patients with established disease, CV death, heart attack, or stroke rates were 4.52 percent for patients with CAD and 5.35 percent for patients with PAD. The incidences of CV death, heart attack, or stroke or of hospitalization for atherothrombotic event(s) were 15.20 percent for CAD, 14.53 percent for CVD, and 21.14 percent for PAD patients with established disease. These event rates increased directly with the number of symptomatic arterial disease locations, from 5.31 percent for patients with risk factors only, to 12.58 percent for patients with one, 21.14 percent for patients with two and 26.27 percent for patients with three symptomatic arterial disease locations.

"The high event rates observed in this large, stable, contemporary outpatient cohort of patients with established atherosclerotic arterial disease or with multiple atherothrombotic risk factors indicate that continued efforts are needed to improve secondary prevention and clinical outcomes. Initiatives to improve adherence to evidence-based guidelines and care are an important tool in this respect. In addition, the strong association of asymptomatic and symptomatic multiple locations of atherothrombosis with event rates suggests that atherothrombosis should be addressed as a global arterial disease in patients," the authors conclude.

Source-Eurekalert
PRI
'"/>




Related medicine news :

1. Atherothrombosis Associated With High Rates of Cardiovascular Events
2. One in Three Heart Attack Patients Have No Chest Pains
3. Amphetamines Help Recovery of Stroke Patients
4. Painkillers Do Not Shorten Dying Patients Lives
5. Patients With Filariasis More Prone To HIV Infection
6. Glivec - New Hope For CMC Patients
7. Patients often assume wrongly that they are allergic to penicillin
8. New FDA Approved Drug NATRECOR For Heart Failure Patients
9. Hemochromatosis Patients Blood is Safe
10. Patients Pressure Would Result In Overprescription
11. Risk Of Decongestants In Hypertensive Patients
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/2/2016)... ... December 02, 2016 , ... On Dec. 2, 2016, CURE® magazine will ... Diego honoring the 2016 MPN Heroes—eight individuals who have made a difference in the ... beyond the standard of care, demonstrating leadership within the MPN community and/or a commitment ...
(Date:12/2/2016)... CO (PRWEB) , ... December 02, 2016 , ... Advanced ... announced it has appointed Jason Bice, CPA, MBA to serve as Advanced Inc.’s Chief ... for Advanced, Inc. , Jason brings extensive financial and operational leadership experience to ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... The annual ... Enrollment Period (or Annual Election Period), is ending December 7th. Currently-enrolled Medicare beneficiaries who ... C) or prescription drug plan (Part D) need to make changes during this period ...
(Date:12/2/2016)... NY (PRWEB) , ... December 02, 2016 , ... ... an inspirational interview of two ostomy patients, standing as living proof that attitude ... suffer from digestive diseases and issues that spike around the holidays. This campaign ...
(Date:12/2/2016)... ... 2016 , ... Mediaplanet is proud to announce the launch ... innovative treatments, therapeutic technologies, and revolutionized nutrition that are helping patients and physicians ... years in the last 3 decades,” says Dr. Valentine Fuster, a world-renowned cardiologist. ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... Dec. 2, 2016  Eli Lilly and Company (NYSE: ... for 2017 and provide updated financial guidance for 2016 ... a conference call on that day with the investment ... guidance. The conference call will begin at ... can access a live webcast of the conference call ...
(Date:12/2/2016)... bioLytical Laboratories, ein Weltführer bei schnellen Tests für Infektionskrankheiten, hat sein ... eingeführt. Continue Reading ... ... , ... ) bioLytical wurde durch die Clinton Health Access ...
(Date:12/2/2016)... , Dec. 2, 2016 Boston Scientific ... definitive agreement to acquire certain manufacturing assets and capabilities ... (TSX: NVC) advanced biological tissue business, as well as ... of $75 million in cash. The Neovasc advanced biological ... including the Boston Scientific Lotus™ Valve System. * ...
Breaking Medicine Technology: